Table 4.
Number and percentages of in situ PLA positive cases for sialyl Lewis carbohydrate–mucin glycopeptides evaluated by in situ PLA in mucinous adenocarcinomas from different locations
| Carbohydrate–mucin | Stomach (n = 4) n (%) | Ampulla (n = 2) n (%) | Colon (n = 7) n (%) | Lung (n = 4) n (%) | Breast (n = 6) n (%) | Ovary (n = 5) n (%) | Total (n = 28) n (%) |
|---|---|---|---|---|---|---|---|
| SLea-MUC1 | 3 (75) | 2 (100) | 4 (57) | 1 (25) | 2 (33) | 4 (80) | 16 (57) |
| SLea-MUC2 | 3 (75) | 2 (100) | 5 (71) | 2 (50) | 2 (33) | 1 (20) ↓ | 15 (54) ↓ |
| SLea-MUC5AC | 2 (50) | 1 (50) | 2 (29) | 1 (25) | 1 (17) | 3 (60) ↓ | 10 (36) ↓ |
| SLea-MUC6 | 0 (0) | 1 (50) | 0 (0) | 0 (0) | 0 (0) | 1 (20) ↓ | 2 (7) ↓ |
| SLex-MUC1 | 4 (100) | 2 (100) | 6 (86) | 3 (75) | 4 (67) | 4 (80) | 23 (82) |
| SLex-MUC2 | 4 (100) | 2 (100) | 5 (71) ↓ | 2 (50) | 2 (33) | 0 (0) | 15 (54) ↓ |
| SLex-MUC5AC | 2 (50) | 1 (50) | 3 (43) ↓ | 2 (50) | 1 (17) | 4 (80) | 13 (46) ↓ |
| SLex-MUC6 | 0 (0) | 1 (50) | 0 (0) | 1 (25) | 1 (17) | 2 (40) | 5 (18) |
↓indicates a decrease in the number of PLA positive cases compared to the number of cases where co-localization was observed (Table 2).